Skip to main content

Divi’s Lab: Unveiling New Avenues for Earnings Growth

Divi’s Lab: Unveiling New Avenues for Earnings Growth

In the dynamic landscape of pharmaceuticals, Divi’s Lab (CMP: Rs 3,655; Market cap: Rs 97,026 crore) stands as a player with the potential to redefine its earnings trajectory through emerging growth opportunities. 

Despite a sequential dip in sales in Q1FY24, the company showcased a positive trend in margins, laying the groundwork for a promising future. Let's delve into the areas that could reshape Divi's Lab's fortunes and drive its success.

Weathering the Storm

The Q1FY24 results, displaying a decline in sales, need context to be understood. This drop can be attributed to the pass-through of lower raw material costs. On a brighter note, there was a notable improvement in the EBITDA margin. 

This was partly due to the exhaustion of high-cost inventory and decreased operating expenses. While pricing challenges persist in the generic portfolio, the company’s growth prospects lie in diverse fields that could redefine its earnings trajectory.

Unlocking Growth: Contrast Media and Beyond

Intriguing growth opportunities lie ahead for Divi’s Lab in the realm of contrast media, peptide building blocks, and carotenoids. Among these, the contrast media sector holds substantial promise. 

The company has already established its foothold in iodine-based contrast media for CT/X-Ray scans and is actively working to enhance yields and iodine recovery efficiency. The expansion into MRI-based contrast media or Gadolinium compounds could be a significant move, with the formulation market size nearing $7 billion. Despite a handful of players in this space, Divi’s Lab is well-positioned to make a meaningful impact.

Margin Matters and Market Outlook

While Q1FY24 saw a consistent contribution from the custom synthesis segment (40% of sales), it marked a decrease from the previous year when sales of the COVID drug Molnupiravir provided a boost. 

Nutraceuticals, accounting for 10% of sales, maintained steady performance. The share of exports stood at 86%, with Europe and the US being the primary contributors (67% of sales).

An improvement in EBITDA margins on a sequential basis was largely driven by factors such as reduced raw material prices, lower logistic expenses, and yield improvements. 

However, a YoY analysis, accounting for forex fluctuations, showed a margin contraction of approximately 700 bps due to changes in the COVID-related business landscape.

Expanding Horizons: Carotenoids and Beyond

One of Divi’s Lab’s strategies to optimize its operations involves the construction of Unit-3 with an initial outlay of Rs 1,500 crore. 

This unit is anticipated to manufacture Key Starting Materials (KSMs), nutraceuticals, and intermediates. This move is expected to create additional capacity for carotenoids/nutraceuticals. With existing carotenoid capacity running at 95%, this expansion could provide a much-needed boost.

The Road Ahead

Despite a gradual expected growth in the near term, Divi’s Lab has a plethora of promising opportunities on the horizon. 

As it explores areas like contrast media, sartans, carotenoids, and patented molecules, the company is guided by its belief that the recent drug master filings (DMFs) will contribute to growth beyond FY25. 

Additionally, Divi’s Lab is poised to enhance its market share for established molecules through the application of innovative technologies that optimize production while minimizing costs and environmental impact.

The company's foray into peptide building blocks, driven by ongoing trials of patented amino acid molecules, underscores its commitment to innovation and custom synthesis. With such potential drivers of growth and improvement in margins, Divi’s Lab has positioned itself as a frontrunner in the API segment.

After a consolidation period of about 22 months, Divi’s Lab's stock is now trading at 29x FY25e EBITDA, signaling the market's confidence in its potential. 

While valuation remains ahead of peers, the company's strategic moves and growth prospects warrant optimism. 

With progress on the Kakinada construction front and promising ventures into novel molecular segments, Divi’s Lab is primed for success. 

As a testament to its potential to harness emerging opportunities, we recommend an ‘overweight’ stance on the stock. Investors looking to ride the upcycle in the API segment and seize the company's growth potential should consider accumulating the stock. 

The path ahead for Divi’s Lab is paved with innovation, diversification, and potential wealth creation.


Popular posts from this blog

Inspirational Story Of Ferrari - Amazing Adviser

Inspirational  Story Of Ferrari Hello friends, today I'm going to discuss one of the most popular sports car companies in the world - Ferrari. Today, each sports car lover dreams to get a Ferrari. It keeps gaining popularity till today. This company was founded by Enzo Ferrari. So let's get to know the success story of Ferrari. Also Read, Success Story Of Amul Success Story of Dominos Pizza The story starts with 18 Feb 1898 when Enzo Ferrari was born in Italy. Enzo was fond of cars right from his childhood. At 10 yrs of age, he went to see a car race with his father.  At that point in time, he decided that he would become a racing driver. After that, he attended many car races. After completing his graduation from Modena College, he worked as a teacher.  But after a few months, he had to join the Italian army for the first World War. In 1916, he suffered a lot with emotions as well as the economy when his brother and father died. After returning from World War, he began to find

Inspirational Story Of BMW - Amazing Adviser

  The wonder of science has shown many miracles in today's age in the form of spectacular vehicles.  Today I will discuss about a German company that specializes in designing cars, bikes and engines - BMW. It came into being before 101 years and is known for its expensive and luxury cars like Rolls Royce and Mini.  But do you know that BMW was in the list of those companies which were restricted to produce any kind of vehicles during the time of World War?  And in that period, this company started making bicycles and kitchen utensils.  Now let's go to the beginning of the story.  Also Read Success Story Of Ambassador Car   Success Story Of Jaguar   Success Story Of UBER     The founder of BMW was Karl Friedrich Rapp. He was born on 24 September 1882 in Germany.  He became a mechanical engineer and opened his start up named Karl Rapp Motorenwerke where mostly aircrafts and their engines were made.  When the first world war started, there was a huge demand of aero engines.  Thus,

Success Story Of Colgate, One Of The Bestselling Toothpaste Brand

Success Story Of Colgate, One Of The Bestselling Toothpaste Brand "It cleans your breath while it cleans your teeth", can you guess whose slogan is this.  If you have guessed correct then today I'm going to tell you the success story of one of the best selling toothpaste brands of India i. e. Colgate.  It's popularity can be measured by thousands of situations where the term toothpaste is replaced by Colgate in India.  Do you know, this brand came into being almost 210 years ago, introduced by Williams Colgate .  And initially, this company used to produce soaps, not toothpaste that too in jars and not tubes.  So now, let's get back to the beginning of the story.  Also Read Success Story Of Haldiram Bujhia Success Story Of Amul How Maggie Became Successful? The founder of Colgate, Willam Colgate was born on 25 Jan 1783 in England. His father was a farmer.  But later, they shifted to Maryland in the US where his father along with a friend began to make candles